Oestrogen receptor β and tamoxifen therapy in breast cancer
Author Information
Author(s): W R Miller, T J Anderson, J M Dixon, P T K Saunders
Primary Institution: University of Edinburgh
Hypothesis
Does the expression of oestrogen receptor β influence the response of breast cancers to tamoxifen treatment?
Conclusion
The expression of ERβ1 and the ERβ2/βcx variant in ERα-positive breast tumours is not associated with a response to tamoxifen treatment.
Supporting Evidence
- 70% of patients showed a clinical response to tamoxifen treatment.
- ERα levels decreased in most tumours after treatment.
- ERβ1 levels increased in 17 out of 33 tumours after treatment.
Takeaway
This study looked at how a specific protein in breast cancer cells affects how well the cancer responds to a common treatment. It found that this protein doesn't help predict if the treatment will work.
Methodology
The study assessed tumour levels of oestrogen receptors in 36 postmenopausal women with ERα-positive breast cancers before and after 3 months of tamoxifen treatment.
Limitations
Data were only presented for 33 patients due to exhaustion of tumour blocks for other studies.
Participant Demographics
All participants were postmenopausal women aged between 56 and 80 years with large ERα-positive breast cancers.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website